Myomo, Inc. MYO
At closeNov 5, 2026, 5:41 AM EST
Pre-market · Nov 5, 5:41 AM ET
- YTD
- +42.86%
- 1 year
- +50.64%
- Market cap
- 51.49M
- Revenue (ttm)
- 25.24M
- Profit margin
- -33.22%
- EPS (ttm)
- -0.35
- Shares out
- 33.70M
- Forward P/E
- -120.60
- YTD return
- +42.86%
- 1-year return
- +50.64%
- Volume
- 165.95K
- Avg volume
- 462.15K
- Open
- 1.35
- Previous close
- 1.28
- Day's range
- 1.26 – 1.33
- 52-week range
- 0.605 – 1.89
- Beta
- 1.55
- Analysts
- Strong Buy
- Price target
- 7.67 (+489.7%)
5D +0.02 (+1.63%)
Key statistics
- Enterprise value
- 178.72M
- PEG ratio
- 0.00
- Price / sales
- 8.05
- Price / book
- 19.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 81.30%
- Free cash flow
- -6.20M
- Total cash
- 6.62M
- Total debt
- 234.63K
- Return on equity
- -82.54%
- Short % of float
- 2.68%
- 50-day average
- 4.85
- 200-day average
- 4.03
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 7.67
- Target (high)
- 9.00
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.022.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.04 | -0.03 | +0.01 | +25.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.07 | -0.03 | +0.04 | +57.14% |
| May 8, 2024 | Mar 1, 2024 | -0.09 | -0.10 | -0.01 | -11.11% |
| Mar 7, 2024 | Dec 1, 2023 | -0.05 | -0.07 | -0.02 | -40.00% |
| Nov 7, 2023 | Sep 1, 2023 | -0.08 | -0.06 | +0.02 | +25.00% |
| Aug 9, 2023 | Jun 1, 2023 | -0.04 | -0.04 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | Craig-Hallum | main | Buy | Buy |
| Nov 12, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 19, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 31, 2024 | Craig-Hallum | init | — | Buy |
| Jul 9, 2024 | Lake Street | main | Buy | Buy |
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- myomo.com
News
Myomo to Attend the 17th Annual Craig Hallum Alpha Select Conference 
Myomo to Report Third Quarter 2026 Financial Results on November 9 
Myomo Q2 2026 Earnings Call Transcript 
Ascendiant Capital Maintains Buy on Myomo, Raises Price Target to $10.5 
12 Health Care Stocks Moving In Thursday's Intraday Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
Myomo Raises FY2026 Sales Guidance from $43.000M-$46.000M to $45.000M-$47.000M vs $44.434M Est - 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Ascendiant Capital Maintains Buy on Myomo, Raises Price Target to $10
12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on MYO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CROWLEY THOMAS ALOYSIUS JR | Director | Stock Award(Grant) | Jun 4, 2024 | 42,028 |
| GETZ HEATHER C | Director | Stock Award(Grant) | Jun 4, 2024 | 12,034 |
| GUDONIS PAUL R | Chief Executive Officer | Stock Award(Grant) | Jun 4, 2024 | 959,845 |
| HENRY DAVID A | Chief Financial Officer | Stock Award(Grant) | Jun 4, 2024 | 414,419 |
| KIRK THOMAS F | Director | Stock Award(Grant) | Jun 4, 2024 | 248,533 |
| KNAPP AMY K | Director | Stock Award(Grant) | Jun 4, 2024 | 91,645 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 9.99% | 3,021,391 | 18.22M | Sep 29, 2024 |
| AIGH Capital Management LLC | 9.19% | 2,778,848 | 16.76M | Sep 29, 2024 |
| Vanguard Group Inc | 4.11% | 1,242,907 | 7.49M | Sep 29, 2024 |
| Essex Investment Management Co LLC | 2.97% | 899,135 | 5.42M | Sep 29, 2024 |
| Legato Capital Management LLC | 1.02% | 307,271 | 1.85M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.76% | 229,098 | 1.38M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.86% | 866,170 | 5.22M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.14% | 346,162 | 2.09M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.42% | 127,531 | 769.01K | Oct 30, 2024 |
| 1290 Fds-1290 Essex Small Cap Growth Fd | 0.38% | 114,763 | 692.02K | Jul 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 67,500 | 407.02K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.21% | 63,396 | 382.28K | Oct 30, 2024 |